Abbott Laboratories Corporation

Julie Yamaguchi

Sushil G Devare

Catherine A Brennan

Robert K Hickman

John R Hackett

Alan M Golden

Suresh M Desai

James M Casey

Donald E Frail

Billy J Zeck

Suzanne L Bode

Anadruzela S Vallari

Vera Holzmayer

Shinichi Watanabe

The present invention relates to Human Immunodeficiency Virus-1 (HIV-1) Group P of the strain designated 06CMU14788 and fragments thereof, primers which are derived from HIV-1 Group P, immunogenic regions thereof, immunoassays and nucleic acid based assays for the detection of Human Immunodeficiency Virus (HIV) that employ said HIV-1 Group P or fragments thereof and therapeutic compositions containing said HIV-1 Group P or fragments thereof.

Human immunodeficiency virus and uses thereof

Isolated HIV-1 Group O env polypeptides obtained from the HIV-1 isolate HAM112 are claimed, as well as (a) antigen constructs comprising fusions of one or more of each of HIV-1 Group O env polypeptides and HIV-1 Group M env polypeptide and (b) further antigen constructs containing additional Group O sequences and especially the gp41 IDR of isolate HAM112. Also claimed are polynucleotide sequences encoding the above, expression vectors comprising the same, host cells transformed thereby, and immunoassay methods and kits utilizing the antigen constructs of the invention.

Antigen constructs useful in the detection and differentiation of antibodies to HIV

Mammalian expression systems for the production of HCV fusion proteins. Such expression systems provide high yields of HCV fusion proteins, and enable the development of diagnostic and therapeutic reagents which contain glycosylated structural antigens and also allow for the isolation of the HCV etiological agent.

Hepatitis C virus fusion proteins

Mammalian expression systems for the production of HCV proteins. Such expression systems provide high yields of HCV proteins, and enable the development of diagnostic and therapeutic reagents which contain glycosylated structural antigens and also allow for the isolation of the HCV etiological agent.

Mammalian expression systems for HCV proteins

Mammalian expression systems for the production of HCV E1-E2 fusion proteins. Such expression systems provide high yields of HCV proteins extracelluarly, and enable the development of diagnostic, vaccine and therapeutic reagents which contain glycosylated structural antigens and also allow for the isolation of the HCV etiological agent.

Mammalian expression systems for hepatitis C virus envelope genes

Growing community of inventors

Chicago, IL, United States of America

Julie Yamaguchi